Healthcare Industry News: Corixa
News Release - January 25, 2006
Trubion Names Michelle Burris Senior Vice President and CFOSEATTLE, Jan. 25 (HSMN NewsFeed) -- Trubion Pharmaceuticals, Inc. today announced the appointment of Michelle Burris to the newly-created position of senior vice president and chief financial officer. Burris, a seasoned public- company finance executive, brings 20 years of financial management and planning experience to Trubion.
"We are delighted to add an executive of Michelle's caliber to the Trubion management team," said Trubion chief executive officer Dr. Peter A. Thompson. "Her arrival coincides with an exciting period of growth and accomplishment for Trubion. We will benefit from her vast experience as we advance our proprietary SMIP pharmaceutical pipeline, execute on our newly formed alliance with Wyeth, and pursue new opportunities for value creation."
Burris served as senior vice president and chief financial officer for Dendreon Corporation until her recent resignation. Prior to Dendreon, she spent more than 10 years at Corixa Corporation, most recently as senior vice president and chief financial officer, where she participated in the development and approval of Bexxar®, an antibody drug approved for the treatment of non-Hodgkin's lymphoma, the negotiation of rights to the drug, and the eventual sale of Corixa to GlaxoSmithKline. Burris also played an integral role in raising over $400 million of capital through public offerings, other equity transactions and company acquisitions. Prior to entering the biotechnology field, she served in numerous management positions at The Boeing Company and, prior to that, as a research analyst at Cypress International Inc., a technology consulting firm.
"I am excited to be joining Trubion. The company's combination of a proven leadership team, validated technology, deep pipeline, and tremendous growth prospects makes for a compelling opportunity," said Ms. Burris.
Burris sits on the Board of Directors at Sonus Pharmaceuticals Inc. and the Washington Biotechnology and BioMedical Association, and she chairs the Executive Advisory Board of the Albers School of Business and Economics at Seattle University. She holds a Post Graduate Certificate in accounting and a Master of Business Administration from Seattle University, and a Bachelor of Science degree from George Mason University.
Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies. Trubion has multiple drug candidates in pre-clinical and clinical development. For additional information visit http://www.trubion.com .
Source: Trubion Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.